Chimaeribacter arupi a new member of the Yersineacea family has the characteristics of a human pathogen

Chimaeribacter arupi (heterotypic synonym: “Nissabacter archeti”) is a facultative anaerobic, newly described Gram-negative rod and belongs to the Yersineacea family. Here, we report the case of a 19-month-old female infant patient who presented to the emergency unit with somnolence and fever. C. arupi was isolated from a positive blood culture, taken via an implanted Broviac catheter, proving a bloodstream infection by the pathogen. The objective of this study was to utilize whole genome sequencing to assess the genes encoding potential virulence associated factors, which may play a role in host tropism, tissue invasion and the subsequent stages in the pathogenesis of a bloodstream infection with C. arupi. The genome of the isolate was completely sequenced employing Illumina MiSeq and Nanopore MinION sequencing and the presumptive virulence associated factors and antimicrobial resistance genes were investigated in more detail. Additionally, we performed metabolic profiling and susceptibility testing by microdilution. The presence of predicted TcfC-like α-Pili suggests that C. arupi is highly adapted to humans as a host. It utilizes flagellar and type IV pili-mediated motility, as well as a number of γ1-pili and a σ-pilus, which may be used to facilitate biofilm formation and adherence to host epithelia. Additionally, long polar fimbriae may aid in tissue invasion. The bacterium possesses antioxidant factors, which may enable temporary survival in phagolysosomes, and a capsule that potentially provides protection from phagocytosis. It may acquire iron ions from erythrocytes through the type 6 secretion system and hemolysins. Furthermore, the isolate exhibits beta-lactamase-mediated penicillin and aminopenicillin resistance. Based on the analysis of the whole genome, we conclude that C. arupi possesses virulence factors associated with tissue invasion and may thus be a potential opportunistic pathogen of bloodstream infections

Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial

Background Current guidelines recommend that patients with Staphylococcus aureus bloodstream infection (SAB) are treated with long courses of intravenous antimicrobial therapy. This serves to avoid SAB-related complications such as relapses, local extension and distant metastatic foci. However, in certain clinical scenarios, the incidence of SAB-related complications is low. Patients with a low-risk for complications may thus benefit from an early switch to oral medication through earlier discharge and fewer complications of intravenous therapy. The major objective for the SABATO trial is to demonstrate that in patients with low-risk SAB a switch from intravenous to oral antimicrobial therapy (oral switch therapy, OST) is non-inferior to a conventional course of intravenous therapy (intravenous standard therapy, IST). Methods/Design The trial is designed as randomized, parallel-group, observer-blinded, clinical non-inferiority trial. The primary endpoint is the occurrence of a SAB-related complication (relapsing SAB, deep-seated infection, and attributable mortality) within 90 days. Secondary endpoints are the length of hospital stay; 14-day, 30-day, and 90-day mortality; and complications of intravenous therapy. Patients with SAB who have received 5 to 7 full days of adequate intravenous antimicrobial therapy are eligible. Main exclusion criteria are polymicrobial bloodstream infection, signs and symptoms of complicated SAB (deep-seated infection, hematogenous dissemination, septic shock, and prolonged bacteremia), the presence of a non-removable foreign body, and severe comorbidity. Patients will receive either OST or IST with a protocol-approved antimicrobial and are followed up for 90 days. Four hundred thirty patients will be randomized 1:1 in two study arms. Efficacy regarding incidence of SAB-related complications is tested sequentially with a non-inferiority margin of 10 and 5 percentage points. Discussion The SABATO trial assesses whether early oral switch therapy is safe and effective for patients with low-risk SAB. Regardless of the result, this pragmatic trial will strongly influence the standard of care in SAB. Trial registration ClinicalTrials.gov NCT01792804 registered 13 February 2013; German Clinical trials register DRKS00004741 registered 4 October 2013, EudraCT 2013-000577-77. First patient randomized on 20 December 2013

Survival following Staphylococcus aureus bloodstream infection; a prospective multinational cohort study assessing the impact of place of care

Background Staphylococcus aureus bloodstream infection (SAB) is a common, life-threatening infection with a high mortality. Survival can be improved by implementing quality of care bundles in hospitals. We previously observed marked differences in mortality between hospitals and now assessed whether mortality could serve as a valid and easy to implement quality of care outcome measure. Methods We conducted a prospective observational study between January 2013 and April 2015 on consecutive, adult patients with SAB from 11 tertiary care centers in Germany, South Korea, Spain, Taiwan, and the United Kingdom. Factors associated with mortality at 90 days were analyzed by Cox proportional hazards regression and flexible parametric models. Results 1,851 patients with a median age of 66 years (64% male) were analyzed. Crude 90-day mortality differed significantly between hospitals (range 23% to 39%). Significant variation between centers was observed for methicillin-resistant S. aureus, community-acquisition, infective foci, as well as measures of comorbidities, and severity of disease. In multivariable analysis, factors independently associated with mortality at 90 days were age, nosocomial acquisition, unknown infective focus, pneumonia, Charlson comorbidity index, SOFA score, and study center. The risk of death varied over time differently for each infective focus. Crude mortality differed markedly from adjusted mortality. Discussion We observed significant differences in adjusted mortality between hospitals, suggesting differences in quality of care. However, mortality is strongly influenced by patient mix and thus, crude mortality is not a suitable quality indicator

Impact of immunosuppressive agents on clinical manifestations and outcome of staphylococcus aureus bloodstream infection: a propensity score-matched analysis in 2 large, prospectively evaluated cohorts

BACKGROUND: Staphylococcus aureus bloodstream infection (SAB) is a common, life-threatening infection. The impact of immunosuppressive agents on the outcome of patients with SAB is incompletely understood. METHODS: Data from 2 large prospective, international, multicenter cohort studies (Invasive Staphylococcus aureus Infections Cohort [INSTINCT] and International Staphylococcus aureus Collaboration [ISAC]) between 2006 and 2015 were analyzed. Patients receiving immunosuppressive agents were identified and a 1:1 propensity score-matched analysis was performed to adjust for baseline characteristics of patients. Overall survival and time to SAB-related late complications (SAB relapse, infective endocarditis, osteomyelitis, or other deep-seated manifestations) were analyzed by Cox regression and competing risk analyses, respectively. This approach was then repeated for specific immunosuppressive agents (corticosteroid monotherapy and immunosuppressive agents other than steroids [IMOTS]). RESULTS: Of 3188 analyzed patients, 309 were receiving immunosuppressive treatment according to our definitions and were matched to 309 nonimmunosuppressed patients. After propensity score matching, baseline characteristics were well balanced. In the Cox regression analysis, we observed no significant difference in survival between the 2 groups (death during follow-up: 105/309 [33.9%] immunosuppressed vs 94/309 [30.4%] nonimmunosuppressed; hazard ratio [HR], 1.20 [95% confidence interval {CI}, .84-1.71]). Competing risk analysis showed a cause-specific HR of 1.81 (95% CI, .85-3.87) for SAB-related late complications in patients receiving immunosuppressive agents. The cause-specific HR was higher in patients taking IMOTS (3.69 [95% CI, 1.41-9.68]). CONCLUSIONS: Immunosuppressive agents were not associated with an overall higher mortality. The risk for SAB-related late complications in patients receiving specific immunosuppressive agents such as IMOTS warrants further investigations

Impact of adherence to individual quality-of-care indicators on the prognosis of bloodstream infection due to Staphylococcus aureus: a prospective observational multicentre cohort

Objectives: To analyse the adherence and impact of quality-of-care indicators (QCIs) in the management of Staphylococcus aureus bloodstream infection in a prospective and multicentre cohort. Methods: Analysis of the prospective, multicentre international S. Aureus Collaboration cohort of S. Aureus bloodstream infection cases observed between January 2013 and April 2015. Multivariable analysis was performed to evaluate the impact of adherence to QCIs on 90-day mortality. Results: A total of 1784 cases were included. Overall, 90-day mortality was 29.9% and mean follow-up period was 118 days. Adherence was 67% (n = 1180/1762) for follow-up blood cultures, 31% (n = 416/ 1342) for early focus control, 77.6% (n = 546/704) for performance of echocardiography, 75.5% (n = 1348/ 1784) for adequacy of targeted antimicrobial therapy, 88.6% (n = 851/960) for adequacy of treatment duration in non-complicated bloodstream infections and 61.2% (n = 366/598) in complicated blood-stream infections. Full bundle adherence was 18.4% (n = 328/1784). After controlling for immortal time bias and potential confounders, focus control (adjusted hazard ratio = 0.76; 95% CI, 0.59-0.99; p 0.038) and adequate targeted antimicrobial therapy (adjusted hazard ratio = 0.75; 95% CI, 0.61-0.91; p 0.004) were associated with low 90-day mortality. Discussion: Adherence to QCIs in S. Aureus bloodstream infection did not reach expected rates. Apart from the benefits of application as a bundle, focus control and adequate targeted therapy were inde-pendently associated with low mortality. Francesc Escrihuela-Vidal, Clin Microbiol Infect 2023;29:498 (c) 2022 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/)

Characterisation and Localization of Toxoplasma gondii Catalase: Peroxisomes in Apicomplexa?

Toxoplasma gondii ist ein obligat intrazellulärer, einzelliger Parasit aus dem Phylum der Apicomplexa. Infektionen des Menschen mit T. gondii verlaufen meist subklinisch. Nach einer Infektion persistiert der Erreger für viele Jahre in Hirn- und Muskelgewebe. Durch Reaktivierung des Erregers, z. B. durch eine Immunschwächekrankheit oder unter Immunsuppression, kann eine Enzephalitis mit septischer Streuung entstehen. Eine diaplazentare Infektion führt zur Fetopathia toxoplasmotica mit Früh- und Totgeburten oder zu der typischen enzephalitischen Trias aus Chorioretinitis, Hydrozephalus und zerebralen Verkalkungen. Ein Mechanismus, der es T. gondii ermöglicht im Wirtsorganismus zu überleben, ist die ungewöhnlich hohe Widerstandsfähigkeit gegenüber freien Radikalen. Die wichtigste Quelle für freie Radikale bei der Abwehrreaktion des Wirtsorganismus ist Wasserstoffperoxid (H2O2 ). Es wird beim sogenannten „respiratory burst“ von Makrophagen freigesetzt, diffundiert dann durch biologische Membranen und schädigt DNA, Lipide und Proteine durch Zerfall in Sauerstoffradikale. Außerdem entsteht (H2O2 ) auch bei normalen Stoffwechselvorgängen in den Persoxisomen der Zelle. Das Enzym Katalase (EC 1.11.1.6) wandelt zweiWasserstoffperoxidmoleküle in Wasser und Sauerstoff um und eliminiert somit toxisches Wasserstoffperoxid. Katalase liegt zumeist in spezialisierten Zellorganellen, den Peroxisomen oder Microbodies, vor. Dort dient es zum Abbau von bei metabolischen Prozessen entstehendem Wasserstoffperoxid. Im Rahmen der vorliegenden Arbeit wurde die Katalase von Toxoplasma gondii kloniert und charakterisiert. Die Klonierung von T. gondii Katalase cDNA ergab ein Protein mit 502 Aminosäuren und einem errechneten Gewicht von 57.2 kDa mit starker Homologie zu anderen eukaryontischen Katalasen. Ein polyklonales Antiserum gegen ein GST-Fusionsprotein zeigte imWestern-blot eine Bande bei ungefähr 63 kDa. Die Immunfluoreszenz zeigte ein vesikuläres Kompartiment im vorderen Ende des Parasiten. Dieses kann von anderen Zellorganellen (Mikronemen, Rhoptrien, Granula densa und dem Apikoplast) durch doppelte Immunfluoreszenzmarkierung unterschieden werden. Zytochemisch können Katalasen durch die DAB-Präzipitationstechnik nachgewiesen werden. Hier zeigten sich vesikuläre Strukturen vor dem Nukleus in der Lichtmikroskopie und runde, spezifische Präzipitate mit einem Durchmesser von 100 bis 300nm in der Elektronenmikroskopie. Am C-terminus der T. gondii Katalase findet sich ein „peroxisomales Targeting Signal“ (PTS1) in den letzten 3 Aminosäuren (-AKM). Die Expression der vollständigen Katalase in CHO-Zellen resultiert in einer peroxisomalen Lokalisation, während ein Konstrukt ohne die letzten 3 Aminosäuren im Zytosol verbleibt. Wird das PTS1 mit einem Reporterprotein (Chloramphenicol-Acetyltransferase) fusioniert, wechselt dessen Lokalisation vom Zytosol zu den Peroxisomen. Damit wurde gezeigt, daß das PTS1 der T. gondii Katalase in einem heterologen System sowohl im Kontext der Katalase als auch eines Reporterproteins den Import in Peroxisomen vermitteln kann. Diese Ergebnisse sind die ersten Hinweise auf Peroxisomen in einem Parasiten der Apikomplexa. Zugleich ist T. gondii, evolutionsbiologisch gesehen, der bisher niedrigste Eukaryont in dem bisher Peroxisomen nachgewiesen wurden.Toxoplasma gondii is a unicellular parasite that is remarkably resistant to hydrogen peroxide. We cloned and sequenced the gene for T. gondii catalase (EC 1. 11.1.6), a peroxisomal marker enzyme in eukaryotes. The gene predicts a protein of about 57.2 kDa and 502 amino acids and has a strong homology to other eukaryotic catalases. By immunofluorescence T. gondii catalase is present primarily in a punctate staining pattern anterior to the parasite nucleus. This compartment can be distinguised from other parasite organelles, namely micronemes, rhoptries, dense granules, and the apicoplast. Cytochemical visualization of catalase using diaminobenzidine precipitation gives a vesicular staining pattern anterior to the nucleus at the light level and shows round structures with an estimated diameter of 100-300 nm by electron microscopy. T. gondii catalase exhibits a putative C-terminal peroxisomal targeting signal in the last 3 amino acids (-AKM). Expression of T. gondii catalase in a mammalian cell line results in peroxisomal localization, whereas a construct lacking the targeting signal remains in the cytosol. Furthermore, addition of -AKM to the C terminus of chloramphenicol acetyltransferase is sufficient to target this protein to peroxisomes